MedTrace Logo

Clinical Concordance Study Between Watson for Oncology and Clinician Practice

NCT03400514 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2018-01-18

No results posted yet for this study

Summary

At present, Watson for Oncology has been applied in 14 countries worldwide, including China, the United States, Holland, Thailand, India, Korea, Poland, Slovakia and Bangladesh. In a double-blind study involving 362 patients in India, treatment recommendations from Watson for Oncology (WFO) performed a high degree of consistency with their multidisciplinary tumor board. The investigators would recruit cancer patients diagnosed as lung cancer, breast cancer, gastric cancer, colon cancer， rectal cancer，cervical cancer or ovarian cancer according to the criteria of Watson for Oncology ，using the updated version of Watson for Oncology to explore the concordance of therapeutic regimen between WFO and physicians in the Affiliated Hospital of Qingdao University.

Conditions

  • Cancer
  • Artificial Intelligence

Sponsors & Collaborators

  • Qingdao University

    lead OTHER

Principal Investigators

  • Xiaochun Zhang · The Affiliated Hospital of Qingdao University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-12
Primary Completion
2018-12-31
Completion
2019-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03400514 on ClinicalTrials.gov